

NEUROLOGY ORDER SET

P: 877.365.5566 | **F:** 855.889.2946

PATIENT INFORMATION	ON: Fax completed form, insurance information, and clinical documentation to 855.889.2	2946
Patient Name:	DOB: Phone:	
	Therapy Continuing Therapy Next Treatment Date:	
MEDICAL INFORMATIO	ON	
	(required) Allergies:	
Lab orders:	Frequency : □ Each infusion □ Other: □ Paragon □ Referring provider	
THERAPY ORDER	- Faragon - Referring provider	
Diagnosis	Infusion Orders	
☐ Pompe Disease ICD-10:		vear
Transpersional Transpersion Inc.	Premedication: Zofran: ☐ 4mg IVP ☐ 8mg IV ☐ Pepcid IV 20mg IVP ☐ Toradol 30mg IVP	year
☐ Acute Migraines	□ Solu-Medrol 125mg IVP □ Reglan 10mg IV □ Benadryl 25mg IV Protocol: □ Depacon: □ 500mg □ 750mg IV □ Magnesium Sulfate 1gm	
ICD-10:	DHE 45: 0.5mg 1mg IV in 100mL NS (must premed for nausea)	
	Standing PRN Order: 1 month 2 months 3 months Repeat regimen daily for days	s/wk
☐ Migraines ICD-10:		
☐ MS ☐ Other: ICD-10:	□ Solu-Medrol 1gm IV daily xday(s) OR □ Solu-Cortef 1gm IV daily x day	/(s)
□ Diagnosis:	Soliris: 900mg IV weekly for the first 4 weeks, followed by 1200mg for the fifth dose 1 w	
ICD-10:	(neuro dosing) later, then 1200mg every 2 weeks thereafter x1 year (inital start with maintenanc later) 1200mg IV every 2 weeks x1 year (maintenance dosing)	:e)
☐ Multiple Sclerosis	□ Tysabri 300mg IV every 4 weeks x1 year (after registering patient with TOUCH) □ Ocrevus* □ 300mg IV at 0 and 2 weeks, then 600mg IV every 6 months x1 year □ 600mg IV every 6 months x1 year □ Ocrevus Zunovo 920mg/23,000units subcutaneously every 6 months x1 year Premed protocol: dexamethasone 20mg PO & cetirizine 10mg PO 30 minutes prior to Ocrevus Zur □ Briumvi* □ 150mg IV x1, then 450mg IV 2 weeks later, followed by 450mg IV every 24 weeks x1 y □ 450mg IV every 24 weeks x1 year * Premed Protocol : Solu-Medrol 100mg IV and Benadryl 25mg PO/IV to be given 30 minutes before infusio	year
☐ Diagnosis:	IVIg Orders: mg/kg OR gm/kg IV divided over day	
ICD-10:	Frequency: Every weeks x1 year OR one time dose only Preferred brand: (Paragon to choose if not indicated)	
□ Diagnosis: Myasthenia Gravis	Ultomiris: Loading dose: □ 2,400mg (40-59kg) □ 2,700mg (60-99kg) □ 3,000mg (100kg (neuro dosing) IV followed 2 weeks later by Maintenance dose of: □ 3,000mg (40-59kg) □ 3,300mg (60-99kg) □ 3,600mg IV (100kg+) IV every 8 weeks x1 year Vyvgart*: □ 10mg/kg IV once weekly for 4 weeks (<120kg)	
☐ Diagnosis: CIDP (Vyvgart Hytrulo)	*Cycle may be repeated >50 days from start of previous cycle. Subsequent cycles may be ordered as appropriate Vyvgart Hytrulo : □ 1,008 mg / 11,200 units subcutaneously	!
ICD-10:	Francisco II Tura alchi far 4 maalia* OD Tayari maali y 1 maar	_
	Rystiggo** : □ <50kg: 420mg □ 50kg to <100kg: 560mg □ ≥100kg: 840mg subQ weekly x6	
☐ hATTR amyloidosis ICD-10:	**Cycle may be repeated ≥63 days from start of previous cycle. Subsequent cycles may be ordered as appropriate □ Amvuttra 25mg SubQ every 3 months x1 year	,
	☐ Tylenol 1000mg PO ☐ Cetirizine 10mg PO ☐ Benadryl 25mg PO ☐ Benadryl 25mg IV	
Pre-medication Orders	☐ Loratadine 10mg PO ☐ Cetirizine 10mg IV ☐ Solu-Medrol mg IVP ☐ Other:	
PROVIDER INFORMATI	ION	
agent in dealing with medical and prescription i	you are authorizing Paragon Healthcare, Inc. and its employees to serve as your prior authorization and specialty pharmacy design insurance companies, and to select the preferred site of care for the patient. Signature: Phone: Fax: Contact Person: ting site of care (if checked, please list site of care):	
PREFERRED LOCATION		
City:	@##P	

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





COMPREHENSIVE SUPPORT FOR NEUROLOGY THERAPY

PATIENT INFORMATION:		
Patient Name: DOB:		
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL		
☐ Include signed and completed order (MD/prescriber to complete page 1)		
☐ Include patient demographic information and insurance information		
☐ Include patient's medication list		
☐ Supporting clinical notes (H&P) to support primary diagnosis		
Has the patient tried and failed previous drug therapy?		
If yes, which drug(s)?		
☐ Labs attached		
☐ JCV antibody (Tysabri orders)		
AChR antibody (Rystiggo, Vyvgart & Ultomiris) or MuSK antibody (Rystiggo)		
☐ Hepatitis B antigen and Hepatitis B core total (Ocrevus & Briumvi orders)		
☐ Serum immunoglobulins (Ocrevus & Briumvi)		
☐ Other supporting labs based on diagnosis/order		
☐ Diagnostic testing		
☐ MRI documentation (Tysabri, Ocrevus, Briumvi)		
☐ Other diagnostic testing to support diagnosis/order		
☐ Vaccine record		
☐ Meningococcal vaccinations - both Men B and Men ACWY (Soliris & Ultomiris orders)		
Other medical necessity:		

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance